Journal ArticleDOI
Adjuvant radiotherapy to sites of previous bulky disease in patients stage iv diffuse large cell lymphoma
Reads0
Chats0
TLDR
This treatment sequence produced durable control disease in patients with disseminated DLCL and bulky disease with acceptable toxicity in patients who received no radiotherapy.Abstract:
Purpose: To evaluate the usefulness of adjuvant radiotherapy to sites of previous bulky disease in patients with advanced diffuse large cell lymphoma (DLCL) who were in complete remission after chemotherapy. Methods and Material: Two-hundred and eighteen patients were initially treated with combined chemotherapy CEOP-bleo (cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin) alternating with DAC (dexamethasone, cytosine arabinoside, and cisplatinum). One hundred and fifty-five patients achieved complete remission. Eighty-eight patients with initial bulky disease were randomly assigned to either received (43 patients) or not received radiotherapy (45 patients). Dose ranged from 40–50 Gy. Results: The median time to treatment failure has not been reached in patients who received radiotherapy. At 5 years 72% of the patients treated with the combined therapy remain alive disease in free compared to only 35% in the control group. Projected survival at 5 years was better in the patients with adjuvant radiotherapy: 81 % compared to 55% in the patients who received no radiotherapy. Toxicity was mild and manageable. No lethal toxicities were observed. Conclusion: This treatment sequence produced durable control disease in patients with disseminated DLCL and bulky disease with acceptable toxicity. The role of radiation therapy in patients with disseminated DLCL will be confirmed in large clinical trials, but we felt that this sequence of treatment could be useful in patients with this clinical condition.read more
Citations
More filters
Book
Non-Hodgkin's Lymphomas
Andrew D. Zelenetz,Ranjana H. Advani,John C. Byrd,Myron S. Czuczman,Lloyd E. Damon,Madeleine Duvic,Luis Fayad,Andres Forero,Martha Glenn,Jon P. Gockerman,Leo I. Gordon,Nancy L. Harris,Richard T. Hoppe,Steven M. Horwitz,Mark S. Kaminski,Youn H. Kim,Ann S. LaCasce,A P Nademanee,Elise Olsen,Pierluigi Porcu,Oliver W. Press,Leonard R. Prosnitz,Mitchell R. Smith,Eduardo M. Sotomayor,Julie M. Vose,Joachim Yahalom,Furhan Yunus +26 more
TL;DR: In this article, different subtypes of non-Hodgkin's lymphoma (NHL) were compared using histological and immunohistochemical methods, including the normal lymph node structure and function.
Journal ArticleDOI
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.
Laurie H. Sehn,Randy D. Gascoyne +1 more
TL;DR: It will be necessary to prioritize drugs that affect key driver pathways and to combine them rationally to optimize their benefit and improve prognostication and the availability of predictive biomarkers will be crucial to allow for the possibility of individualized risk-adapted therapy.
Journal ArticleDOI
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
Michael Pfreundschuh,Anthony D. Ho,Eva Cavallin-Ståhl,Max Wolf,Ruth Pettengell,Ingrid Vášová,Andrew Belch,Jan Walewski,Pier Luigi Zinzani,Walter Mingrone,Stein Kvaløy,Ofer Shpilberg,Ulrich Jaeger,Mads Hansen,Claudia Corrado,Adriana Scheliga,Markus Loeffler,Evelyn Kuhnt +17 more
TL;DR: The effect of maximum tumour diameter (MTD) in young patients treated with CHOP-like chemotherapy with or without rituximab did not eliminate young patients with good-prognosis diffuse large-B-cell lymphoma, and an adverse prognostic effect of MTD on EFS and OS was shown.
Journal ArticleDOI
Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma
Gerhard Held,Niels Murawski,Marita Ziepert,Jochen Fleckenstein,Viola Pöschel,Carsten Zwick,Jörg Thomas Bittenbring,Mathias Hänel,Sibylla Wilhelm,Jörg Schubert,Norbert Schmitz,Markus W. Löffler,Christian Rübe,Michael Pfreundschuh +13 more
TL;DR: Additive RT to bulky sites abrogates bulky disease as a risk factor and improves outcome of elderly patients with aggressive B-cell lymphoma.
Journal ArticleDOI
Treatment of non-Hodgkin's lymphoma of waldeyer's ring: Radiotherapy versus chemotherapy versus combined therapy
TL;DR: Combined therapy should be considered as the best therapeutic approach in patients with localised NHL of Waldeyer's ring after radiotherapy alone, combined chemotherapy and combined therapy.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
A generalized Wilcoxon test for comparing arbitrarily singly-censored samples
TL;DR: Some comparisons are made for five cases of varying degrees of censoring and tying between probabilities from the exact test and those from the proposed test and these suggest the test is appropriate under certain conditions when the sample size is five in each group.
Journal ArticleDOI
Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).
William S. Velasquez,Fernando Cabanillas,Patricio G. Salvador,Peter McLaughlin,M Fridrik,S Tucker,Sundar Jagannath,F. B. Hagemeister,Redman,F Swan +9 more
TL;DR: DHAP has proven to be an effective non-crossresistant regimen for patients with relapsing or refractory lymphoma, particularly for patients who have favorable prognostic characteristics.
Journal ArticleDOI
Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.
Bertrand Coiffier,Christion Gisselbrecht,Julie M. Vose,Hervé Tilly,Raoul Herbrecht,André Bosly,James O. Armitage +6 more
TL;DR: In patients with aggressive lymphomas, this simple prognostic index could distinguish between patients requiring intensive treatment such as autologous bone marrow transplantation in first complete remission and those who could be treated with standard regimens.
Related Papers (5)
A predictive model for aggressive non-Hodgkin's lymphoma
Margaret A. Shipp,D. P. Harrington,James R. Anderson,James Olen Armitage,Gianni Bonadonna,G. Brittinger,Fernando Cabanillas,George P. Canellos,Bertrand Coiffier,Joseph M. Connors,R. A. Cowan,D. Crowther,Steve Dahlberg,M. Engelhard,Richard I. Fisher,Christian Gisselbrecht,Sandra J. Horning,Eric Lepage,T. A. Lister,J. H. Meerwaldt,Emili Montserrat,Nis I. Nissen,M. M. Oken,Bruce A. Peterson,Carlo Tondini,W. A. Velasquez,B. Y. Yeap +26 more